A Phase 1 Study of BMF-500 in Adults With Acute Leukemia
← catalyst calendarSponsored by Biomea Fusion Inc. (industry) · BMEA — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
35actual
Sites
14
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-07-26 | actual | When the study began enrolling |
| Primary completion | Apr 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2023-06-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Acute Myeloid Leukemia
Intervention
- Drug: BMF-500
Primary outcomes
what the primary-completion date above is the date OFEvaluate the safety and tolerability of BMF-500 by incidence of Treatment Emergent Adverse Events (TEAEs).
measured At the end of each 28 Day cycle for a maximum of 32 cycles
Evaluate the safety and tolerability of BMF-500 by incidence of Serious Adverse Events (SAEs).
measured At the end of each 28 Day cycle for a maximum of 32 cycles
Determine the recommended Phase 2 Dose (RP2D) of BMF-500.
measured At the end of 28 day Dose-Limiting Toxicities (DLT) observation Period
Determine the recommended Phase 2 Dose (RP2D) of BMF-500.
measured At the end of 28 day Dose-Limiting Toxicities (DLT) observation Period
Determine the recommended Phase 2 Dose (RP2D) of BMF-500.
measured At the end of 28 day Dose-Limiting Toxicities (DLT) observation Period
Determine the recommended Phase 2 Dose (RP2D) of BMF-500.
measured At the end of 28 day Dose-Limiting Toxicities (DLT) observation Period
Permalink · BMEA's whole pipeline · Catalyst calendar · Every registered study · What changed